News

Masitinib treatment was linked to a nearly doubled five-year survival rate among people with amyotrophic lateral sclerosis (ALS), with higher survival rates seen among patients with slower disease progression and those who started treatment before experiencing a complete loss of functionality. That’s according to new analyses from the…

Neurosense Therapeutics said it recently held a “constructive” meeting with Health Canada to discuss potential regulatory pathways for PrimeC, its experimental oral therapy for amyotrophic lateral sclerosis (ALS). The meeting focused on the company’s proposed new drug submission (NDS) strategy and the clinical, biomarker, and long-term outcomes data…

Researchers using a fish model of amyotrophic lateral sclerosis (ALS) found that damage to the cerebellum — a brain region not traditionally associated with ALS — begins before motor symptoms emerge. This damage appears to be driven by reduced levels of PAICS, an enzyme involved in the production of…

A team at Stanford University has received a $13 million grant to uncover previously unknown genetic causes of amyotrophic lateral sclerosis (ALS), with the goal of identifying targets for future treatments. The grant, awarded by the California Institute for Regenerative Medicine (CIRM) to a team led by Stanford…

The statistical methods scientists use to analyze outcomes from clinical trials in amyotrophic lateral sclerosis (ALS) vary widely, and these differences may make some trials prone to generating misleading results, a study found. The researchers focused on analysis of the ALS Functional…

Two leaders at Brainstorm Cell Therapeutics, which is developing the experimental cell-based therapy NurOwn (debamestrocel) for people with amyotrophic lateral sclerosis (ALS), have published a paper calling on the U.S. Food and Drug Administration (FDA) to modernize its review process for experimental therapies for ALS and other…

Several nonprofits are uniting to fund new research aimed at identifying targets for the treatment of amyotrophic lateral sclerosis (ALS). The new initiative will be led by the Allen Institute, a nonprofit medical research organization, through its Brain Health Accelerator — a research initiative to study neurodegenerative diseases. The…

PAS-004, an experimental therapy that Pasithea Therapeutics is developing to address inflammation and TDP-43 protein clumps, has received orphan drug designation by the U.S. Food and Drug Administration for the treatment of amyotrophic lateral sclerosis (ALS). The status aims to accelerate the development of therapies for rare diseases, or…

An arm of the HEALEY ALS platform trial testing Neurizon Therapeutics’ experimental therapy NUZ-001 as a treatment for amyotrophic lateral sclerosis (ALS) is expanding enrollment from 160 to as many as 240 participants. The decision follows enrollment that exceeded original expectations and the absence of another HEALEY regimen…

Regulatory authorities in the Netherlands have given the green light for a clinical trial testing Ability Neurotech‘s experimental brain-implantable technology as a way to restore communication and speech in people with amyotrophic lateral sclerosis (ALS). The study is designed to assess whether the system can support independent communication…